References of "Expert Review of Pharmacoeconomics & Outcomes Research"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailMacro-economic factors influencing the architectural business model shift in the pharmaceutical industry
Dierks, Raphaela Marie Louisa ULg; Bruyère, Olivier ULg; Reginster, Jean-Yves ULg et al

in Expert Review of Pharmacoeconomics & Outcomes Research (2016), First online

Introduction: Technological innovations, new regulations, increasing costs of drug productions and new demands are only few key drivers of a projected alternation in the pharmaceutical industry and its ... [more ▼]

Introduction: Technological innovations, new regulations, increasing costs of drug productions and new demands are only few key drivers of a projected alternation in the pharmaceutical industry and its underlying business model. Despite significant articles in the press, there is little medical and economic evidence on the rationale driving the transformation from the traditional Research & Development (R&D) model to new alternative business models, such as Mergers & Acquisitions (M&A). The purpose of this review is to understand the macro-economic factors responsible for the revolution of the pharmaceutical business model, by understanding the needs, desires, new behavioral patterns, but also challenges within the industry. Considering these changes will be the key to possessing a competitive advantage over the market players. Areas covered: Existing literature on new macro-economic factors changing the pharmaceutical landscape has been reviewed to present a clear image of the current market environment. Expert commentary: Literature and media sources show that pharmaceutical companies are facing an architectural alteration in their business model, with more M&A deals and collaborations headlining the papers. Although Q1 2016 did show a major slowdown in M&A deals by volume since 2013 (with deal cancellations of Pfizer and Allergan, or the downfall of Valeant) pharmaceutical analysts remain confident that this shortfall was a consequence of the equity market volatility. It seems likely that the shift to an M&A model will become apparent during the remainder of 2016, with deal announcements such as Abbott Laboratories, AbbVie and Sanofi worth USD 45billion [1] showing the appetite of big pharma companies to shift from the fully vertical integrated business model to more horizontal business models. [less ▲]

Detailed reference viewed: 38 (11 ULg)
Full Text
Peer Reviewed
See detailCost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women.
Hiligsmann, Mickaël ULg; Boonen, Annelies; Dirksen, Carmen D. et al

in Expert review of pharmacoeconomics & outcomes research (2013), 13(1), 19-28

Denosumab is a novel biological agent for the treatment of osteoporosis in postmenopausal women with increased risk of fractures. With limited healthcare resources, economic evaluations are increasingly ... [more ▼]

Denosumab is a novel biological agent for the treatment of osteoporosis in postmenopausal women with increased risk of fractures. With limited healthcare resources, economic evaluations are increasingly being used by decision-makers to optimize healthcare resource allocation. The cost-effectiveness of denosumab has been evaluated in various studies, and a systematic literature study was conducted up to April 2012 to identify all published research articles and research abstracts presented at various congresses. This article provides a systematic review of four articles and eight abstracts reporting on the cost-effectiveness of denosumab in the treatment of osteoporosis. In most economic evaluations, denosumab has been considered as a cost-effective treatment compared with first-line and second-line options (including generic alendronate) in the treatment of women with high risk of fractures. [less ▲]

Detailed reference viewed: 29 (7 ULg)
Full Text
Peer Reviewed
See detailCost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis
Hiligsmann, Mickaël ULg; Vanoverberghe, Marie ULg; Neuprez, Audrey ULg et al

in Expert Review of Pharmacoeconomics & Outcomes Research (2010), 10(4), 359-366

Strontium ranelate has recently been introduced for the prevention and treatment of osteoporosis in Europe and in many countries worldwide. This study aims to review the published cost-effectiveness ... [more ▼]

Strontium ranelate has recently been introduced for the prevention and treatment of osteoporosis in Europe and in many countries worldwide. This study aims to review the published cost-effectiveness literature pertaining to strontium ranelate. Six studies were identified: two in United Kingdom, two in Belgium and two in Sweden. The findings were consistent across the literature, suggesting that strontium ranelate is a cost-saving drug for women with osteoporosis aged over 80 years of age, and it is a cost-effective treatment compared with no treatment for osteoporotic women aged over 70 years and for younger women with clinical risk factors for fragility fracture. Strontium ranelate was also shown to be cost-effective compared with branded risedronate in osteoporotic women over 75 years. Further analyses are required to assess effectiveness and adherence to strontium ranelate in real-life settings, as well as to evaluate the cost-effectiveness of strontium ranelate in other countries and in populations of men. [less ▲]

Detailed reference viewed: 57 (2 ULg)
Full Text
Peer Reviewed
See detailOvercoming problems with adherence to osteoporosis medication.
Rabenda, Véronique ULg; Reginster, Jean-Yves ULg

in Expert review of pharmacoeconomics & outcomes research (2010), 10(6), 677-89

Nonadherence to pharmacological treatment in osteoporosis is a well-recognized problem. As in other chronic diseases, adherence to osteoporosis treatment is poor, resulting in enormous burden on patients ... [more ▼]

Nonadherence to pharmacological treatment in osteoporosis is a well-recognized problem. As in other chronic diseases, adherence to osteoporosis treatment is poor, resulting in enormous burden on patients and healthcare resources. Most importantly, low adherence rates consistently result in increased rates of fractures. However, it seems that efforts to evaluate and improve rates of both compliance and persistence are increasing. The extension of dosing intervals may be an element, among others, allowing improvements in therapeutic adherence. Improved patient education, enhancing healthcare provider-patients interaction, taking into account patient's preferences and involving them in treatment decisions may improve adherence. [less ▲]

Detailed reference viewed: 26 (2 ULg)